Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399230 | 0.80 | CYP2A6 (0.53) | GAAGRM4HTTMTOR | |
| SCHEMBL3143603 | 0.77 | NPC1 (0.50) | GAARAB9ANPC1GRM4MTOR | |
| SCHEMBL9191311 | 0.75 | NPC1 (0.60) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL515503 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL2784980 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL255496 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL152495 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL221485 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL19542254 | 0.74 | GAA (0.59) | GAAHPGDSALKBH2RAB9ANPC1 | |
| SCHEMBL2419571 | 0.74 | GAA (1.00) | GAAHPGDSALKBH2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-9840504-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-08-31 | — | — | US | disclosed |
| EP-3191484-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9375008-B2 | Pyrazole compounds for controlling invertebrate pests | BASF SE (DE) | 2016-06-28 | — | — | US | disclosed |
| CN-104211688-B | The pyrazole compound of controlling invertebrate pests | BASF SE (DE) | 2016-04-13 | — | — | CN | disclosed |
| EP-1343798-A1 | 6-O-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046204-A1 | 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | GAA 1048/4885HPGDS 1107/4885ALKBH2 3952/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | GAA 988/4885HPGDS 1233/4885ALKBH2 1308/4885 |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | GAA 1048/4885HPGDS 1107/4885ALKBH2 3952/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | GAA 990/4885HPGDS 1179/4885ALKBH2 1598/4885 |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | TPP1, PRDX5, TPMT | GAA 1048/4885HPGDS 1107/4885ALKBH2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.